EXCESSIVE DIETARY-PROTEIN AND SUBOPTIMAL CALORIC-INTAKE HAVE A NEGATIVE EFFECT ON THE GROWTH OF CHILDREN WITH CHRONIC RENAL-DISEASE BEFORE AND DURING GROWTH-HORMONE THERAPY
Z. Zadik et al., EXCESSIVE DIETARY-PROTEIN AND SUBOPTIMAL CALORIC-INTAKE HAVE A NEGATIVE EFFECT ON THE GROWTH OF CHILDREN WITH CHRONIC RENAL-DISEASE BEFORE AND DURING GROWTH-HORMONE THERAPY, Metabolism, clinical and experimental, 47(3), 1998, pp. 264-268
Although diet and nutrition are an integral part of the management of
individuals with chronic renal failure (CRF), little has been written
on the effect of nutrition on the growth response to growth hormone (G
H) in CRF. We studied the GH axis and nutritional status of 31 prepube
rtal children aged 8.7 +/- 0.5 years with a height standard deviation
score (SDS) of -3.2 +/- 0.2 (mean +/- SEM) with CRF. Sixteen CRF patie
nts on hemodialysis and 15 on peritoneal dialysis were studied, Forty-
four age-matched normal short children without GH deficiency served as
controls, Spontaneous 12-hour GH and stimulated GH values were signif
icantly higher and GH binding protein (GHBP) was significantly lower i
n the CRF patients than in the normal short children. Both before the
initiation of GH therapy and after the first year of treatment, the gr
owth velocity (SDS) was inversely correlated with dietary protein inta
ke and positively correlated with caloric intake. GH was administered
at a dosage of 28 and 21 IU/m(2)/wk to the CRF group and the normal sh
ort children, respectively, divided into seven daily doses. The growth
response of the normal short children was significantly greater than
that of the CRF patients. GH therapy induced a smaller increment in GH
BP and IGF-I in the CRF patients versus the normal short children (8.8
+/- 2.2 and 10.2 +/- 2.7 v 24.8 +/- 1.3 and 27.6 +/- 2.5 nmol/L, resp
ectively, P < .01). The 1-year growth velocity of the CRF children was
most closely correlated with dietary protein and caloric intake. The
nutritional status of CRF patients is concluded to be a major factor i
n growth both before and during GH therapy. Copyright (C) 1998 by W.B.
Saunders Company.